Search

Your search keyword '"Van Hemelrijck, Mieke"' showing total 1,986 results
Start Over Author "Van Hemelrijck, Mieke"
1,986 results on '"Van Hemelrijck, Mieke"'

51. Real-world data evaluating Guy’s rapid diagnostic clinic as an alternate pathway for patients with FIT levels below 10

Author

Monroy-Iglesias, Maria Jose, primary, Martin, Sabine, additional, Cargaleiro, Carlos, additional, Jones, Geraint, additional, Steward, Lindsay, additional, Murtagh, Colette, additional, Bruno, Flaminia, additional, Millwaters, Juliet, additional, Schizas, Alexis, additional, Watson, Harriet, additional, Haire, Anna, additional, Haire, Kate, additional, Moss, Charlotte Louise, additional, Russell, Beth, additional, Srirajaskanthan, Raj, additional, Van Hemelrijck, Mieke, additional, and Dolly, Saoirse, additional

Published
2024
Full Text
View/download PDF

53. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer

Author

Smith, Emma Jane, N'Dow, James, Plass, Karin, Ribal, Maria, Mottet, Nicolas, Shepherd, Robert, Moris, Lisa, Lardas, Michael, Van den Broeck, Thomas, Willemse, Peter-Paul, Campi, Riccardo, Gacci, Mauro, Bjartell, Anders, Evans-Axelsson, LU Susan, Briganti, Alberto, Gandaglia, Giorgio, Crosti, Daniele, Meoni, Massimiliano, Garzonio, Roberto, Bangma, Chris, Roobol, Monique, Remmers, Sebastiaan, Tilki, Derya, Auvinen, Anssi, Murtola, Teemu, Visakorpi, Tapio, Talala, Kirsi, Tammela, Teuvo, Siltari, Aino, Van Hemelrijck, Mieke, Beyer, Katharina, Lejeune, Stephane, van Diggelen, Femke, Byrne, Sophie, Fialho, Luz, Cardone, Antonella, Gono, Paulina, De Meulder, Bertrand, Auffray, Charles, Balaur, Irina-Afrodita, Taibi, Nesrine, Power, Shaun, Kermani, Nazanin Zounemat, van Bochove, Kees, Cirillo, Elisa, Moinat, Maxim, Voss, Emma, Horgan, Denis, Fullwood, Louise, Holtorf, Marc, Lancet, Doron, Bernstein, Gabi, Omar, Imran, MacLennan, Sara, MacLennan, Steven, Tripathee, Sheela, Huber, Johannes, Wirth, Manfred, Froehner, Michael, Brenner, Beate, Borkowetz, Angelika, Thomas, Christian, Horn, Friedemann, Reiche, Kristin, Kreuz, Markus, Josefsson, Andreas, Tandefelt, Delila Gasi, Hugosson, Jonas, Schalken, Jack, Huisman, Henkjan, Hofmarcher, Thomas, Lindgren, Peter, Andersson, Emelie, Fridhammar, Adam, Asiimwe, Alex, Verholen, Frank, Zong, Jihong, Butler-Ransohoff, John-Edward, Williamson, Todd, Chandrawansa, Kumari, Waldeck, Reg, Molnar, Megan, Bruno, Amanda, Herrera, Ronald, Nevedomskaya, Ekaterina, Fatoba, Samuel, Constantinovici, Niculae, Mohamed, Ateesha, Steinbeißer, Carl, Kedhagae, Siddhanth, Maass, Monika, Torremante, Patrizia, Voss, Marc Dietrich, Devecseri, Zsuzsanna, Abbott, Tom, Kiran, Amit, Dau, Chad, Papineni, Kishore, Wang-silvanto, Jing, Hass, Steve, Snijder, Robert, Doyé, Verena, Wang, Xuewei, Garnham, Andy, Lambrecht, Mark, Wolfinger, Russ, Rogiers, Stijn, Servan, Angela, Casariego, Joaquin, Samir, Mohamed, Pascoe, Katie, Robinson, Paul, Reich, Christian, Ratwani, Shilpa, Longden-Chapman, Elaine, Burke, Danny, Agapow, Paul, Derkits, Sahra, Licour, Muriel, Ang, Michelle, Payne, Sarah, Yong, Alan, Thompson, Lucy, Le Mare, Sophia, Bussmann, Michael, Köhler, Inken, Juckeland, Guido, Kotik, Daniel, MacLennan, Sara J., Mastris, Ken, Hooker, Gary, Greene, Robert, Briers, Erik, Omar, Muhammad Imran, Healey, Jemma, Venderbos, Lionne D.F., Smith, Emma J., Bjorkqvist, Josefine, Roobol, Monique J., and N’Dow, James

Published
2021
Full Text
View/download PDF

56. Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination:A systematic review and meta-analysis

Author

Steinberg, Julia, Hughes, Suzanne, Hui, Harriet, Allsop, Matthew J., Egger, Sam, David, Michael, Caruana, Michael, Coxeter, Peter, Carle, Chelsea, Onyeka, Tonia, Rewais, Isabel, Monroy Iglesias, Maria J., Vives, Nuria, Wei, Feixue, Abila, Derrick Bary, Carreras, Giulia, Santero, Marilina, O'Dowd, Emma L., Lui, Gigi, Tolani, Musliu Adetola, Mullooly, Maeve, Lee, Shing Fung, Landy, Rebecca, Hanley, Sharon J.B., Binefa, Gemma, McShane, Charlene M., Gizaw, Muluken, Selvamuthu, Poongulali, Boukheris, Houda, Nakaganda, Annet, Ergin, Isil, Moraes, Fabio Ynoe, Timilshina, Nahari, Kumar, Ashutosh, Vale, Diama B., Molina-Barceló, Ana, Force, Lisa M., Campbell, Denise Joan, Wang, Yuqing, Wan, Fang, Baker, Anna Lisa, Singh, Ramnik, Salam, Rehana Abdus, Yuill, Susan, Shah, Richa, Lansdorp-Vogelaar, Iris, Yusuf, Aasim, Aggarwal, Ajay, Murillo, Raul, Torode, Julie S., Kliewer, Erich V., Bray, Freddie, Chan, Kelvin K.W., Peacock, Stuart, Hanna, Timothy P., Ginsburg, Ophira, Van Hemelrijck, Mieke, Sullivan, Richard, Roitberg, Felipe, Ilbawi, André M., Soerjomataram, Isabelle, Canfell, Karen, Steinberg, Julia, Hughes, Suzanne, Hui, Harriet, Allsop, Matthew J., Egger, Sam, David, Michael, Caruana, Michael, Coxeter, Peter, Carle, Chelsea, Onyeka, Tonia, Rewais, Isabel, Monroy Iglesias, Maria J., Vives, Nuria, Wei, Feixue, Abila, Derrick Bary, Carreras, Giulia, Santero, Marilina, O'Dowd, Emma L., Lui, Gigi, Tolani, Musliu Adetola, Mullooly, Maeve, Lee, Shing Fung, Landy, Rebecca, Hanley, Sharon J.B., Binefa, Gemma, McShane, Charlene M., Gizaw, Muluken, Selvamuthu, Poongulali, Boukheris, Houda, Nakaganda, Annet, Ergin, Isil, Moraes, Fabio Ynoe, Timilshina, Nahari, Kumar, Ashutosh, Vale, Diama B., Molina-Barceló, Ana, Force, Lisa M., Campbell, Denise Joan, Wang, Yuqing, Wan, Fang, Baker, Anna Lisa, Singh, Ramnik, Salam, Rehana Abdus, Yuill, Susan, Shah, Richa, Lansdorp-Vogelaar, Iris, Yusuf, Aasim, Aggarwal, Ajay, Murillo, Raul, Torode, Julie S., Kliewer, Erich V., Bray, Freddie, Chan, Kelvin K.W., Peacock, Stuart, Hanna, Timothy P., Ginsburg, Ophira, Van Hemelrijck, Mieke, Sullivan, Richard, Roitberg, Felipe, Ilbawi, André M., Soerjomataram, Isabelle, and Canfell, Karen

Abstract

While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36-1.61, I2 = 0; people with COVID-19: aOR = 1.58, 95% CI: 1.41-1.77, I2 = 0.58; inpatients with COVID-19: aOR = 1.66, 95% CI: 1.34-2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68-2.68, I2 = 0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37-1.75) at 1 year and aOR = 0.98 (95% CI: 0.80-1.20) at 5 years post-cancer diagnosis/treatment. In conclusion, before CO

Published
2024

57. Survivorship Data in Prostate Cancer:Where Are We and Where Do We Need To Be?

Author

Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, Van Hemelrijck, Mieke, Russell, Beth, Beyer, Katharina, Lawlor, Ailbhe, Roobol, Monique J., Venderbos, Lionne D.F., Remmers, Sebastiaan, Briers, Erik, MacLennan, Sara J., MacLennan, Steven, Omar, Muhammad Imran, and Van Hemelrijck, Mieke

Abstract

Cancer survivorship was recently identified as a prostate cancer (PCa) research priority by PIONEER, a European network of excellence for big data in PCa. Despite being a research priority, cancer survivorship lacks a clear and agreed definition, and there is a distinct paucity of patient-reported outcome (PRO) data available on the subject. Data collection on cancer survivorship depends on the availability and implementation of (validated) routinely collected patient-reported outcome measures (PROMs). There have been recent advances in the availability of such PROMs. For instance, the European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) is developing survivorship questionnaires. This provides an excellent first step in improving the data available on cancer survivorship. However, we propose that an agreed, standardised definition of (prostate) cancer survivorship must first be established. Only then can real-world data on survivorship be collected to strengthen our knowledge base. With more men than ever surviving PCa, this type of research is imperative to ensure that the quality of life of these men is considered as much as their quantity of life. Patient summary: As there are more prostate cancer survivors than ever before, research into cancer survivorship is crucial. We highlight the importance of such research and provide recommendations on how to carry it out. The first step should be establishing agreement on a standardised definition of survivorship. From this, patient-reported outcome measures can then be used to collect important survivorship data.

Published
2024

58. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management:A PIONEER Analysis Based on Big Data

Author

Gandaglia, Giorgio, Pellegrino, Francesco, Golozar, Asieh, De Meulder, Bertrand, Abbott, Thomas, Achtman, Ariel, Imran Omar, Muhammad, Alshammari, Thamir, Areia, Carlos, Asiimwe, Alex, Beyer, Katharina, Bjartell, Anders, Campi, Riccardo, Cornford, Philip, Falconer, Thomas, Feng, Qi, Gong, Mengchun, Herrera, Ronald, Hughes, Nigel, Hulsen, Tim, Kinnaird, Adam, Lai, Lana Y.H., Maresca, Gianluca, Mottet, Nicolas, Oja, Marek, Prinsen, Peter, Reich, Christian, Remmers, Sebastiaan, Roobol, Monique J., Sakalis, Vasileios, Seager, Sarah, Smith, Emma J., Snijder, Robert, Steinbeisser, Carl, Thurin, Nicolas H., Hijazy, Ayman, van Bochove, Kees, Van den Bergh, Roderick C.N., Van Hemelrijck, Mieke, Willemse, Peter Paul, Williams, Andrew E., Zounemat Kermani, Nazanin, Evans-Axelsson, Susan, Briganti, Alberto, N'Dow, James, Gandaglia, Giorgio, Pellegrino, Francesco, Golozar, Asieh, De Meulder, Bertrand, Abbott, Thomas, Achtman, Ariel, Imran Omar, Muhammad, Alshammari, Thamir, Areia, Carlos, Asiimwe, Alex, Beyer, Katharina, Bjartell, Anders, Campi, Riccardo, Cornford, Philip, Falconer, Thomas, Feng, Qi, Gong, Mengchun, Herrera, Ronald, Hughes, Nigel, Hulsen, Tim, Kinnaird, Adam, Lai, Lana Y.H., Maresca, Gianluca, Mottet, Nicolas, Oja, Marek, Prinsen, Peter, Reich, Christian, Remmers, Sebastiaan, Roobol, Monique J., Sakalis, Vasileios, Seager, Sarah, Smith, Emma J., Snijder, Robert, Steinbeisser, Carl, Thurin, Nicolas H., Hijazy, Ayman, van Bochove, Kees, Van den Bergh, Roderick C.N., Van Hemelrijck, Mieke, Willemse, Peter Paul, Williams, Andrew E., Zounemat Kermani, Nazanin, Evans-Axelsson, Susan, Briganti, Alberto, and N'Dow, James

Abstract

BACKGROUND: Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics.OBJECTIVE: To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data.DESIGN, SETTING, AND PARTICIPANTS: From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146).OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data.RESULTS AND LIMITATIONS: The most common comorbidities were hypertension (35-73%), obesity (9.2-54%), and type 2 diabetes (11-28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12-25%) and emergency department visits (10-14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent.CONCLUSIONS: Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and

Published
2024

59. Predictive Models for Assessing Patients’ Response to Treatment in Metastatic Prostate Cancer:A Systematic Review

Author

Lawlor, Ailbhe, Lin, Carol, Gómez Rivas, Juan, Ibáñez, Laura, Abad López, Pablo, Willemse, Peter Paul, Imran Omar, Muhammad, Remmers, Sebastiaan, Cornford, Philip, Rajwa, Pawel, Nicoletti, Rossella, Gandaglia, Giorgio, Yuen-Chun Teoh, Jeremy, Moreno Sierra, Jesús, Golozar, Asieh, Bjartell, Anders, Evans-Axelsson, Susan, N'Dow, James, Zong, Jihong, Ribal, Maria J., Roobol, Monique J., Van Hemelrijck, Mieke, Beyer, Katharina, Lawlor, Ailbhe, Lin, Carol, Gómez Rivas, Juan, Ibáñez, Laura, Abad López, Pablo, Willemse, Peter Paul, Imran Omar, Muhammad, Remmers, Sebastiaan, Cornford, Philip, Rajwa, Pawel, Nicoletti, Rossella, Gandaglia, Giorgio, Yuen-Chun Teoh, Jeremy, Moreno Sierra, Jesús, Golozar, Asieh, Bjartell, Anders, Evans-Axelsson, Susan, N'Dow, James, Zong, Jihong, Ribal, Maria J., Roobol, Monique J., Van Hemelrijck, Mieke, and Beyer, Katharina

Abstract

Background and objective: The treatment landscape of metastatic prostate cancer (mPCa) has evolved significantly over the past two decades. Despite this, the optimal therapy for patients with mPCa has not been determined. This systematic review identifies available predictive models that assess mPCa patients’ response to treatment. Methods: We critically reviewed MEDLINE and CENTRAL in December 2022 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Only quantitative studies in English were included with no time restrictions. The quality of the included studies was assessed using the PROBAST tool. Data were extracted following the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews criteria. Key findings and limitations: The search identified 616 citations, of which 15 studies were included in our review. Nine of the included studies were validated internally or externally. Only one study had a low risk of bias and a low risk concerning applicability. Many studies failed to detail model performance adequately, resulting in a high risk of bias. Where reported, the models indicated good or excellent performance. Conclusions and clinical implications: Most of the identified predictive models require additional evaluation and validation in properly designed studies before these can be implemented in clinical practice to assist with treatment decision-making for men with mPCa. Patient summary: In this review, we evaluate studies that predict which treatments will work best for which metastatic prostate cancer patients. We found that existing studies need further improvement before these can be used by health care professionals.

Published
2024

61. Anxiety and depression in patients with non-site-specific cancer symptoms: data from a rapid diagnostic clinic.

Author

Monroy-Iglesias, Maria J., Russell, Beth, Martin, Sabine, Fox, Louis, Moss, Charlotte, Bruno, Flaminia, Millwaters, Juliet, Steward, Lindsay, Murtagh, Colette, Cargaleiro, Carlos, Bater, Darren, Lavelle, Grace, Simpson, Anna, Onih, Jemima, Haire, Anna, Reeder, Clare, Jones, Geraint, Smith, Sue, Santaolalla, Aida, and Van Hemelrijck, Mieke

Subjects
MENTAL depression, ANXIETY, MACHINE learning, CANCER patients, ANXIETY disorders, SUPPORT vector machines
Abstract

Background: Rapid diagnostic clinics (RDCs) provide a streamlined holistic pathway for patients presenting with non-site specific (NSS) symptoms concerning of malignancy. The current study aimed to: 1) assess the prevalence of anxiety and depression, and 2) identify a combination of patient characteristics and symptoms associated with severe anxiety and depression at Guy's and St Thomas' Foundation Trust (GSTT) RDC in Southeast London. Additionally, we compared standard statistical methods with machine learning algorithms for predicting severe anxiety and depression. Methods: Patients seen at GSTT RDC between June 2019 and January 2023 completed the General Anxiety Disorder Questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-8) questionnaires, at baseline. We used logistic regression (LR) and 2 machine learning (ML) algorithms (random forest (RF), support vector machine (SVM)) to predict risk of severe anxiety and severe depression. The models were constructed using a set of sociodemographic and clinical variables. Results: A total of 1734 patients completed GAD-7 and PHQ-8 questionnaires. Of these, the mean age was 59 years (Standard Deviation: 15.5), and 61.5% (n:1067) were female. Prevalence of severe anxiety (GAD-7 score ≥15) was 13.8% and severe depression (PHQ-8 score≥20) was 9.3%. LR showed that a combination of previous mental health condition (PMH, Adjusted Odds Rario (AOR) 3.28; 95% confidence interval (CI) 2.36-4.56), symptom duration >6 months (AOR 2.20; 95%CI 1.28-3.77), weight loss (AOR 1.88; 95% CI 1.362.61), progressive pain (AOR 1.71; 95%CI 1.26-2.32), and fatigue (AOR 1.36; 95%CI 1.01-1.84), was positively associated with severe anxiety. Likewise, a combination PMH condition (AOR 3.95; 95%CI 2.17-5.75), fatigue (AOR 2.11; 95%CI 1.47-3.01), symptom duration >6 months (AOR 1.98; 95%CI 1.06-3.68), weight loss (AOR 1.66; 95%CI 1.13-2.44), and progressive pain (AOR 1.50; 95%CI 1.04-2.16), was positively associated with severe depression. LR and SVM had highest accuracy levels for severe anxiety (LR: 86%, SVM: 85%) and severe depression (SVM: 89%, LR: 86%). Conclusion: High prevalence of severe anxiety and severe depression was found. PMH, fatigue, weight loss, progressive pain, and symptoms >6 months emerged as combined risk factors for both these psychological comorbidities. RDCs offer an opportunity to alleviate distress in patients with concerning symptoms by expediting diagnostic evaluations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

63. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative

Author

Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Logothetis, Christopher, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Van Hemelrijck, Mieke, Dasgupta, Prokar, Bangma, Chris, Roobol, Monique, Villers, Arnauld, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Shiong, Lee Lui, Frydenberg, Mark, Kakehi, Yoshiyuki, Chung, Byung Ha, van der Kwast, Theo, Obbink, Henk, van der Linden, Wim, Hulsen, Tim, Jonge, Cees de, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Steyerberg, Ewout, Nieboer, Daan, Zhang, Liying, Beckmann, Kerri, Denton, Brian, Hayen, Andrew, Boutros, Paul, Guo, Wei, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Tolosa, Emily, Kim, Tae-Kyung, Mamedov, Alexandre, LaPointe, Vincent, Crump, Trafford, Kimberly-Duffell, Jenna, Santaolalla, Aida, Olivier, Jonathan, Rancati, Tiziana, Ahlgren, Helén, Mascarós, Juanma, Löfgren, Annica, Lehmann, Kurt, Lin, Catherine Han, Hirama, Hiromi, Lee, Kwang Suk, Jenster, Guido, Auvinen, Anssi, Haider, Masoom, van Bochove, Kees, Carter, Ballentine, Gledhill, Sam, Buzza, Mark, Bruinsma, Sophie, Helleman, Jozien, Kalapara, Arveen A., Verbeek, Jan F.M., Lee, Lui Shiong, Bangma, Chris H., Steyerberg, Ewout W., Harkin, Tim, and Roobol, Monique J.

Published
2020
Full Text
View/download PDF

64. AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper

Author

Turner, Michelle C., primary, Radzikowska, Urszula, additional, Ferastraoaru, Denisa E., additional, Pascal, Mariona, additional, Wesseling, Pieter, additional, McCraw, Alexandra, additional, Backes, Claudine, additional, Bax, Heather J., additional, Bergmann, Christoph, additional, Bianchini, Rodolfo, additional, Cari, Luigi, additional, de las Vecillas, Leticia, additional, Izquierdo, Elena, additional, Lind‐Holm Mogensen, Frida, additional, Michelucci, Alessandro, additional, Nazarov, Petr V., additional, Niclou, Simone P., additional, Nocentini, Giuseppe, additional, Ollert, Markus, additional, Preusser, Matthias, additional, Rohr‐Udilova, Nataliya, additional, Scafidi, Andrea, additional, Toth, Reka, additional, Van Hemelrijck, Mieke, additional, Weller, Michael, additional, Jappe, Uta, additional, Escribese, Maria M., additional, Jensen‐Jarolim, Erika, additional, Karagiannis, Sophia N., additional, and Poli, Aurélie, additional

Published
2024
Full Text
View/download PDF

66. A cohort profile of the Graham Roberts study cohort

Author

Russell, Beth, primary, Leech, Poppy, additional, Wylie, Harriet, additional, Moss, Charlotte Louise, additional, Haire, Anna, additional, Enting, Deborah, additional, Amery, Suzanne, additional, Chatterton, Kathryn, additional, Khan, Muhammad Shamim, additional, Thurairaja, Ramesh, additional, Nair, Rajesh, additional, Malde, Sachin, additional, Smith, Kate, additional, Gillett, Cheryl, additional, Josephs, Debra, additional, Pintus, Elias, additional, Rudman, Sarah, additional, Hughes, Simon, additional, Relton, Clare, additional, and Van Hemelrijck, Mieke, additional

Published
2024
Full Text
View/download PDF

67. Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

Author

Vincenzi, Bruno, primary, Cortellini, Alessio, additional, Mazzocca, Alessandro, additional, Orlando, Sarah, additional, Romandini, Davide, additional, Aguilar-Company, Juan, additional, Ruiz-Camps, Isabel, additional, Valverde Morales, Claudia, additional, Eremiev-Eremiev, Simeon, additional, Tondini, Carlo, additional, Brunet, Joan, additional, Bertulli, Rossella, additional, Provenzano, Salvatore, additional, Bower, Mark, additional, Generali, Daniele, additional, Salazar, Ramon, additional, Sureda, Anna, additional, Prat, Aleix, additional, Vasiliki, Michalarea, additional, Van Hemelrijck, Mieke, additional, Sita-Lumsden, Ailsa, additional, Bertuzzi, Alexia, additional, Rossi, Sabrina, additional, Jackson, Amanda, additional, Grosso, Federica, additional, Lee, Alvin J. X., additional, Murphy, Cian, additional, Belessiotis, Katherine, additional, Mukherjee, Uma, additional, Pommeret, Fanny, additional, Loizidou, Angela, additional, Gaidano, Gianluca, additional, Dettorre, Gino M., additional, Grisanti, Salvatore, additional, Tucci, Marco, additional, Fulgenzi, Claudia A. M., additional, Gennari, Alessandra, additional, Napolitano, Andrea, additional, and Pinato, David J., additional

Published
2024
Full Text
View/download PDF

69. Risk of COVID‐19 death for people with a pre‐existing cancer diagnosis prior to COVID‐19‐vaccination: A systematic review and meta‐analysis

Author

Steinberg, Julia, primary, Hughes, Suzanne, additional, Hui, Harriet, additional, Allsop, Matthew J., additional, Egger, Sam, additional, David, Michael, additional, Caruana, Michael, additional, Coxeter, Peter, additional, Carle, Chelsea, additional, Onyeka, Tonia, additional, Rewais, Isabel, additional, Monroy Iglesias, Maria J., additional, Vives, Nuria, additional, Wei, Feixue, additional, Abila, Derrick Bary, additional, Carreras, Giulia, additional, Santero, Marilina, additional, O'Dowd, Emma L., additional, Lui, Gigi, additional, Tolani, Musliu Adetola, additional, Mullooly, Maeve, additional, Lee, Shing Fung, additional, Landy, Rebecca, additional, Hanley, Sharon J. B., additional, Binefa, Gemma, additional, McShane, Charlene M., additional, Gizaw, Muluken, additional, Selvamuthu, Poongulali, additional, Boukheris, Houda, additional, Nakaganda, Annet, additional, Ergin, Isil, additional, Moraes, Fabio Ynoe, additional, Timilshina, Nahari, additional, Kumar, Ashutosh, additional, Vale, Diama B., additional, Molina‐Barceló, Ana, additional, Force, Lisa M., additional, Campbell, Denise Joan, additional, Wang, Yuqing, additional, Wan, Fang, additional, Baker, Anna‐Lisa, additional, Singh, Ramnik, additional, Salam, Rehana Abdus, additional, Yuill, Susan, additional, Shah, Richa, additional, Lansdorp‐Vogelaar, Iris, additional, Yusuf, Aasim, additional, Aggarwal, Ajay, additional, Murillo, Raul, additional, Torode, Julie S., additional, Kliewer, Erich V., additional, Bray, Freddie, additional, Chan, Kelvin K. W., additional, Peacock, Stuart, additional, Hanna, Timothy P., additional, Ginsburg, Ophira, additional, Van Hemelrijck, Mieke, additional, Sullivan, Richard, additional, Roitberg, Felipe, additional, Ilbawi, André M., additional, Soerjomataram, Isabelle, additional, and Canfell, Karen, additional

Published
2023
Full Text
View/download PDF

70. Reply to R. Sun et al

Author

Moore, Jonathan L., primary, Santaolalla, Aida, additional, Van Hemelrijck, Mieke, additional, North, Bernard, additional, and Davies, Andrew R., additional

Published
2023
Full Text
View/download PDF

79. Introduction to Cancer Epidemiology

Author

Van Hemelrijck, Mieke, Holmberg, Lars, Loda, Massimo, editor, Mucci, Lorelei A., editor, Mittelstadt, Megan L., editor, Van Hemelrijck, Mieke, editor, and Cotter, Maura Bríd, editor

Published
2017
Full Text
View/download PDF

82. Generic solution of the heterogeneity-induced competing risk problem in survival analysis

Author

van Baardewijk, Hans, Garmo, Hans, van Hemelrijck, Mieke, Holmberg, Lars, and Coolen, Anthony CC

Subjects
Statistics - Applications
Abstract

Most papers implicitly assume competing risks to be induced by residual cohort heterogeneity, i.e. heterogeneity that is not captured by the recorded covariates. Based on this observation we develop a generic statistical description of competing risks that unifies the main schools of thought. Assuming heterogeneity-induced competing risks is much weaker than assuming risk independence. However, we show that it still imposes sufficient constraints to solve the competing risk problem, and derive exact formulae for decontaminated primary risk hazard rates and cause-specific survival functions. The canonical description is in terms of a cohort's covariate-constrained functional distribution of individual hazard rates of all risks. Assuming proportional hazards at the level of individuals leads to a natural parametrisation of this distribution, from which Cox regression, frailty and random effects models, and latent class models can all be recovered in special limits, and which also generates parametrised cumulative incidence functions (the language of Fine and Gray). We demonstrate with synthetic data how the generic method can uncover and map a cohort's substructure, if such substructure exists, and remove heterogeneity-induced false protectivity and false exposure effects. Application to real survival data from the ULSAM study, with prostate cancer as the primary risk, is found to give plausible alternative explanations for previous counter-intuitive inferences., Comment: 41 pages, 7 figures

Published
2013

87. COmparing Urolift andStandardTransurethral resection of prostateAhead ofRadiotherapy in men with urinary symptoms secondary to prostate enlargement in Southwest London and North Cumbria (CO-STAR): a study protocol for a randomised feasibility study

Author

Wong, Kathie, primary, Kinsella, Netty, additional, Seth, Jai, additional, Nicol, David, additional, Cahill, Declan, additional, Kasivisvanathan, Ramanathan, additional, Withington, John, additional, Moghul, Masood, additional, Moss, Charlotte Louise, additional, Van Hemelrijck, Mieke, additional, Giorgakoudi, Kyriaki, additional, Cottrell, Chris, additional, Yates, Emma, additional, Khoo, Vincent, additional, and James, Nicholas D, additional

Published
2023
Full Text
View/download PDF

89. Prehabilitation exercise before oesophagectomy: long-term follow-up of patients declining/withdrawing from the program

Author

Knight, William, primary, Moore, Jonathan L, additional, Whyte, Greg P, additional, Zylstra, Janine, additional, Lane, Andrew M, additional, Pate, James, additional, Gervais-Andre, Louise, additional, Maisey, Nick, additional, Hill, Mark, additional, Tham, Gemma, additional, Lagergren, Jesper, additional, Kelly, Mark, additional, Baker, Cara, additional, Van Hemelrijck, Mieke, additional, Goh, Vicky, additional, Gossage, James, additional, Browning, Mike, additional, and Davies, Andrew R, additional

Published
2023
Full Text
View/download PDF

90. Cardiopulmonary exercise testing of patients with metastatic castrate-resistant prostate cancer as screening for vigorous exercise medicine prescription.

Author

Newton, Robert Usher, primary, Hart, Nicolas H., additional, Kenfield, Stacey A., additional, Galvao, Daniel Abido, additional, Courneya, Kerry S., additional, Ryan, Charles M, additional, Chan, June M., additional, Catto, James W.F., additional, Winters-Stone, Kerri M., additional, Van Hemelrijck, Mieke, additional, Wylie, Harriet, additional, Schumann, Moritz, additional, Skinner, Tina, additional, Praet, Stephan, additional, and Saad, Fred, additional

Published
2023
Full Text
View/download PDF

91. Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study

Author

Moore, Caroline M, primary, Frangou, Elena, additional, McCartan, Neil, additional, Santaolalla, Aida, additional, Kopcke, Douglas, additional, Brembilla, Giorgio, additional, Hadley, Joanna, additional, Giganti, Francesco, additional, Marsden, Teresa, additional, Van Hemelrijck, Mieke, additional, Gong, Fiona, additional, Freeman, Alex, additional, Haider, Aiman, additional, Tuck, Steve, additional, Pashayan, Nora, additional, Callender, Thomas, additional, Green, Saran, additional, Brown, Louise C, additional, Punwani, Shonit, additional, and Emberton, Mark, additional

Published
2023
Full Text
View/download PDF

92. Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post–COVID-19 Global Context: A Modified Delphi Consensus Process

Author

Fox, Louis, primary, Santaolalla, Aida, additional, Handford, Jasmine, additional, Sullivan, Richard, additional, Torode, Julie, additional, Vanderpuye, Verna, additional, Pramesh, C.S., additional, Mula-Hussain, Layth, additional, AlWaheidi, Shaymaa, additional, Makaroff, Lydia E., additional, Kaur, Ranjit, additional, Mackay, Clara, additional, Mukherji, Deborah, additional, and Van Hemelrijck, Mieke, additional

Published
2023
Full Text
View/download PDF

94. 1935: Early Quality-of-Life after metastases-directed SBRT– results of the ESTRO & EORTC OligoCare cohort

Author

Greto, Daniela, van Hemelrijck, Mieke, Oppong, Felix, Lievens, Yolande, Ratosa, Ivica, Jereczek-Fossa, Barbara Alicja, Stellamans, Karin, Peulen, Heike, Verbeke, Luc, hemmatazad, Hossein, Ramella, Sara, Braam, Pètra, Ivaldi, Giovanni Battista, Zapatero, Almudena, Adnan, Shaukat, Tsoutsou, Pelagia, Cruz, Olalla Santa, Sancho-Pardo, Gemma, Ost, Piet, and Guckenberger, Matthias

Published
2024
Full Text
View/download PDF

96. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data

Author

Gandaglia, Giorgio, primary, Pellegrino, Francesco, additional, Golozar, Asieh, additional, De Meulder, Bertrand, additional, Abbott, Thomas, additional, Achtman, Ariel, additional, Imran Omar, Muhammad, additional, Alshammari, Thamir, additional, Areia, Carlos, additional, Asiimwe, Alex, additional, Beyer, Katharina, additional, Bjartell, Anders, additional, Campi, Riccardo, additional, Cornford, Philip, additional, Falconer, Thomas, additional, Feng, Qi, additional, Gong, Mengchun, additional, Herrera, Ronald, additional, Hughes, Nigel, additional, Hulsen, Tim, additional, Kinnaird, Adam, additional, Lai, Lana Y.H., additional, Maresca, Gianluca, additional, Mottet, Nicolas, additional, Oja, Marek, additional, Prinsen, Peter, additional, Reich, Christian, additional, Remmers, Sebastiaan, additional, Roobol, Monique J., additional, Sakalis, Vasileios, additional, Seager, Sarah, additional, Smith, Emma J., additional, Snijder, Robert, additional, Steinbeisser, Carl, additional, Thurin, Nicolas H., additional, Hijazy, Ayman, additional, van Bochove, Kees, additional, Van den Bergh, Roderick C.N., additional, Van Hemelrijck, Mieke, additional, Willemse, Peter-Paul, additional, Williams, Andrew E., additional, Zounemat Kermani, Nazanin, additional, Evans-Axelsson, Susan, additional, Briganti, Alberto, additional, and N'Dow, James, additional

Published
2023
Full Text
View/download PDF

97. A protocol for the development of core outcome sets for effectiveness trials and clinical audits in renal cell cancer (R‐COS)

Author

MacLennan, Steven, primary, Wintner, Lisa M., additional, Beyer, Katharina, additional, Lawlor, Ailbhe, additional, Tripathee, Sheela, additional, Dabestani, Saeed, additional, Marconi, Lorenzo, additional, Giles, Rachel H., additional, Woodward, Rose, additional, Van Hemelrijck, Mieke, additional, Bex, Axel, additional, and Zondervan, Patricia, additional

Published
2023
Full Text
View/download PDF

98. Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review

Author

Moss, Charlotte L, primary, Guerrero-Urbano, Teresa, additional, White, Ingrid, additional, Taylor, Benjamin, additional, Kristeleit, Rebecca, additional, Montes, Ana, additional, Fox, Louis, additional, Beyer, Katharina, additional, Sztankay, Monika, additional, Ratti, Maria M, additional, Sisca, Elena S, additional, Derevianko, Alexandra, additional, MacLennan, Steven, additional, Wood, Nicholas, additional, Wintner, Lisa M, additional, and Van Hemelrijck, Mieke, additional

Published
2023
Full Text
View/download PDF

100. Cohort profile: King’s Health Partners bladder cancer biobank

Author

Kotecha, Pinky, Moss, Charlotte L., Enting, Deborah, Gillett, Cheryl, Joseph, Magdalene, Josephs, Debra, Rudman, Sarah, Hughes, Simon, Cahill, Fidelma, Wylie, Harriet, Haire, Anna, Rosekilly, James, Khan, Muhammad Shamin, Nair, Rajesh, Thurairaja, Ramesh, Malde, Sachin, and Van Hemelrijck, Mieke

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results